Nipro Of Japan To Begin Marketing Human iPS Cells To Drug Makers
This article was originally published in PharmAsia News
Executive Summary
Japan's Nipro says it plans to launch soon the nation's first sale of cultivated human stem cells to drug makers and research institutes. Nipro said sales should begin in June of cardiac muscle cells developed from human induced pluripotent stem cells. Similar cells from iPS cells in monkeys already are available on the market, but Nipro expects the human samples to enable assessments of drug side effects more readily, improving the speed and efficacy of clinical tests. The cells to be marketed as kits were produced by ReproCell, a Japanese biotech venture. (Click here for more - a subscription may be required
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.